FDA Expands Opioid Abuse Research, Outreach
US agency signs contracts for more real-world data on abuse; officials also meet with AMA representatives to discuss opioid prescriber education.
You may also be interested in...
Contracts US agency awarded as fiscal year 2017 came to a close include one to Nexight for a regenerative medicine standards development process, another to Lorenz to manage eCTD submissions – and 26 more for regulatory science R&D.
Reeducating prescribers on treating pain will take a long time, FDA Commissioner Scott Gottlieb tells Senate HELP Committee Members.
Treatment guidelines may also appear in opioid labeling, and insurers seem to be taking the agency's advice, but will it be enough to satisfy Congress?